Hip Implant Maker Zimmer Biomet Cuts Annual Profit Forecast On Paragon 28 Deal
1. ZBH's Q1 adjusted EPS is $1.81, below last year's $1.94. 2. Sales increased 1.1% to $1.91 billion, matching expectations. 3. Knee and hip product sales performed moderately well. 4. 2025 EPS guidance lowered to $7.90-$8.10, impacting investor confidence. 5. Successful FDA approvals may drive future sales growth.